Recursion Pharmaceuticals has reached an important regulatory milestone after securing alignment with the US Food and Drug Administration (FDA) on the design of a Phase 3 clinical trial for REC-4881, its investigational oral treatment for familial adenomatous polyposis (FAP).
The company announced on November 18, 2026, that the planned study is expected to begin in the second half of 2027 and will evaluate REC-4881 in approximately 200 adults living with FAP who have previously undergone colectomy or proctocolectomy.
REC-4881 is an investigational MEK1/2 inhibitor being developed as a potential first-in-class oral treatment for FAP. The drug candidate was identified through Recursion’s AI-powered drug discovery platform, which uses artificial intelligence and biological data to identify potential new medicines.
A key part of the FDA agreement is the inclusion of adenoma removal as part of the trial’s primary endpoint. Specifically, the study will count the removal of adenomas measuring 10 millimeters or larger in either the upper or lower gastrointestinal (GI) tract as a clinically meaningful event.
Adenomas are abnormal growths that can develop in the digestive tract. In people with FAP, these growths can become cancerous over time. Larger adenomas, particularly those measuring 10 millimeters or more, are associated with an increased risk of high-grade dysplasia and cancer.
The Phase 3 study will be a randomized, double-blind, placebo-controlled trial. Participants will receive either REC-4881 at a planned dose of 4 mg or a placebo. The final dosing schedule will be determined based on results from the ongoing Phase 2 TUPELO study.
The primary endpoint will measure event-free survival, looking at the time until the first occurrence of adenoma removal measuring 10 millimeters or larger, qualifying FAP-related surgery, high-grade dysplasia or cancer, or death from any cause.
The study will also assess changes in modified Spigelman stage and overall polyp burden as secondary endpoints. A planned interim analysis will also be included in the trial design.
FAP is a rare inherited condition that causes numerous polyps to develop in the colon and other parts of the digestive system. People living with the condition often require regular endoscopic monitoring, repeated polyp removal and major surgery to reduce their risk of colorectal cancer. Even after colon removal, patients may continue to develop polyps in other parts of the GI tract.
According to Recursion, results from the Phase 2 TUPELO study showed rapid reductions in polyp burden across the gastrointestinal tract, including larger and higher-risk polyps. These findings supported the company’s decision to advance REC-4881 into a registrational Phase 3 programme.
The latest FDA alignment represents an important step in the development of REC-4881, particularly as there are currently no approved pharmacological therapies specifically available for FAP.
Recursion aims to develop REC-4881 as a potential treatment that could reduce polyp growth, limit repeated medical procedures and improve long-term disease management for people living with FAP.